Shukra Medtech subsidiaries post Rs 5.37 crore half-year loss
Key highlights
- Eight Shukra Medtech subsidiaries reported zero revenue for the half year ended September 30, 2026.
- The eight subsidiaries recorded a combined Rs 5.37 crore loss after tax for the half year ended September 30, 2026.
- The subsidiaries held combined assets of Rs 37.20 lakh before consolidation adjustments at September 30, 2026.
- Shukra Medtech reported consolidated half-year revenue of Rs 68.84 crore and profit before tax of Rs 36.00 crore.
powered by IRIS

Shukra Medtech Limited’s eight subsidiaries reported zero revenue and a combined Rs 5.37 crore loss after tax for the half year ended September 30, 2026, with total assets of Rs 37.20 lakh before consolidation adjustments. The auditor’s review said the subsidiary information was unaudited and furnished by management.
Know Shukra Medtech inside out
Results, valuation, peers and who's buying, in one view.
What did Shukra Medtech’s eight subsidiaries report?
Shukra Medtech’s eight subsidiaries recorded aggregate revenue of zero for both the quarter ended September 30, 2026 and the six months from April 1, 2026 to September 30, 2026. Their total assets before consolidation adjustments were Rs 37.20 lakh as at September 30, 2026, according to the auditor’s review of the consolidated results.
The subsidiaries’ combined loss after tax was Rs 3.30 crore for the September 2026 quarter and Rs 5.37 crore for the half year. Total comprehensive income was also negative Rs 3.30 crore for the quarter and negative Rs 5.37 crore for the half year, matching the loss-after-tax figures disclosed for the eight entities.
The report presents these figures before consolidation adjustments, rather than as a separate line in the group’s consolidated statement. It does not disclose assets, revenue, expenses, funding or losses for any individual subsidiary, so the source does not identify the specific cause of the Rs 5.37 crore half-year loss.
The reported half-year loss was substantially larger than the subsidiaries’ Rs 37.20 lakh aggregate asset base at September 30, 2026. However, the filing provides no prior-period subsidiary asset or profit figures, preventing a period-on-period comparison of their underlying financial position.
Which entities were included in Shukra Medtech’s subsidiary disclosure?
Shukra Medtech’s disclosure covered Shukra Diabetes Technologies Private Limited, Shukra Health Tech Private Limited, Shukra Robotics Private Limited and Shukra Woundcare Private Limited. The same September 30, 2026 review also listed Radiance Aesthetics Private Limited, Shukra Combat Medical Support Pvt Ltd., Shukra Defence Private Limited and Shukra EmergiCare and Virtual Autopsy.
The auditor identified Shukra Medtech as the holding company and referred to the holding company and subsidiaries together as the group for the quarter and half year ended September 30, 2026. The entity list in the report uses the former holding-company name, Shukra Pharmaceuticals Limited, while the report heading identifies Shukra Medtech as formerly known as Shukra Pharmaceuticals Limited.
The filing does not allocate the eight entities between the group’s pharmaceutical and medtech operating segments. It therefore does not establish whether any subsidiary contributed to the medtech segment’s Rs 12.51 crore revenue for the half year ended September 30, 2026.
Shukra Medtech’s segment note says it operates in the Shukra Pharmaceutical and Shukra MedTech segments, with the Shukra MedTech segment name effective from October 1, 2025. That classification is a consolidated reporting presentation and is not an entity-by-entity disclosure for the eight subsidiaries.
Got a follow-up? Ask IRIS
How did the auditor review Shukra Medtech’s subsidiary figures?
The auditor relied solely on unaudited interim financial results and other unaudited financial information that Shukra Medtech’s management approved and furnished for the eight subsidiaries. The auditor stated that its conclusion on the consolidated statement, insofar as it concerned these entities’ amounts and disclosures, was based on that management-provided information.
The review was conducted under Standard on Review Engagement 2410, covering interim financial information reviewed by an entity’s independent auditor. The report states that a review primarily involves inquiries and analytical procedures and has a substantially narrower scope than an audit, meaning it does not provide audit assurance on all significant matters.
The auditor’s conclusion was not modified for the quarter ended September 30, 2026 or the April-to-September 2026 period. It said nothing had come to its attention to indicate that the consolidated statement failed to disclose required information under Regulation 33 of the Securities and Exchange Board of India listing regulations or contained a material misstatement.
The review report described the subsidiaries’ interim financial information as not material to the group. That statement is the auditor’s assessment in the context of the consolidated results and does not alter the disclosed zero revenue, Rs 37.20 lakh asset base or Rs 5.37 crore half-year loss.
How do the subsidiary figures compare with Shukra Medtech’s consolidated results?
Shukra Medtech reported consolidated revenue from operations of Rs 68.84 crore for the half year ended September 30, 2026, up from Rs 14.09 crore in the corresponding half year ended September 30, 2025. Consolidated profit before tax rose to Rs 36.00 crore from Rs 1.57 crore, whereas the subsidiary disclosure reports loss after tax, which is not directly comparable with group profit before tax.
The pharmaceutical segment contributed Rs 56.33 crore of half-year revenue and Rs 33.67 crore of profit before tax and interest. The medtech segment reported Rs 12.51 crore of revenue and Rs 3.10 crore of profit before tax and interest, compared with no revenue or segment result in the corresponding half year of 2025.
Consolidated total assets stood at Rs 175.26 crore at September 30, 2026, compared with Rs 117.44 crore at March 31, 2026. Capital work-in-progress increased to Rs 26.09 crore from Rs 11.91 crore, while inventories increased to Rs 23.42 crore from Rs 13.90 crore over the same period.
Consolidated liabilities increased to Rs 56.71 crore at September 30, 2026 from Rs 27.59 crore at March 31, 2026. Current borrowings rose to Rs 12.87 crore from Rs 1.83 crore and non-current borrowings rose to Rs 9.63 crore from Rs 3.19 crore, but the filing does not link either movement to a particular subsidiary.
Conclusion
The September 2026 review shows a contrast between Shukra Medtech’s consolidated growth and the results of its eight subsidiaries. The group reported Rs 68.84 crore in half-year revenue and Rs 36.00 crore in profit before tax, while the subsidiaries reported no revenue and a combined Rs 5.37 crore loss after tax before consolidation adjustments.
The unresolved point is the source of the subsidiary losses, as the filing gives no entity-level breakdown of expenses, activities or funding for the eight companies. Subsequent disclosures will show whether Shukra Medtech provides more detail on these entities and whether the medtech segment continues to report revenue after contributing Rs 12.51 crore in the half year ended September 30, 2026.


